Go Pro
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$4.06 -0.12 (-2.87%)
As of 04:00 PM Eastern

About Nephros Stock (NASDAQ:NEPH)

Advanced

Key Stats

Today's Range
$4.06
$4.26
50-Day Range
$3.24
$4.76
52-Week Range
$2.66
$6.42
Volume
17,872 shs
Average Volume
32,094 shs
Market Capitalization
$44.09 million
P/E Ratio
25.38
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Nephros, Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing.

Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays.

Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.

AI Generated. May Contain Errors.

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 41% of companies evaluated by MarketBeat, and ranked 642nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Nephros is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Nephros has only been the subject of 4 research reports in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Earnings Growth

    Earnings for Nephros are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is 26.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.29.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is 26.14, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.97.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.44% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 1.66, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently increased by 19.39%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • Search Interest

    Only 1 people have searched for NEPH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Nephros to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    6.70% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEPH Stock News Headlines

Nephros (NEPH) Q2 2026 Earnings Call Transcript
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript
Nephros Launches New HydraGuard 20" UltraFilter
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $4.88 at the start of the year. Since then, NEPH shares have decreased by 14.3% and is now trading at $4.1810.

Nephros Inc. (NASDAQ:NEPH) announced its quarterly earnings data on Thursday, August, 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.00 by $0.06. The business had revenue of $6.02 million for the quarter, compared to analysts' expectations of $4.99 million. Nephros had a net margin of 8.38% and a trailing twelve-month return on equity of 10.60%.
Read the conference call transcript
.

Top institutional investors of Nephros include Cornerstone Capital Inc. (1.19%), Bard Associates Inc. (1.09%), Navellier & Associates Inc. (0.49%) and BlackRock Inc. (0.17%).
View institutional ownership trends
.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/06/2026
Today
9/04/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NASDAQ:NEPH
CIK
1196298
Employees
30
Year Founded
1997

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
-1.5%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.16
Trailing P/E Ratio
25.38
Forward P/E Ratio
27.07
P/E Growth
N/A
Net Income
$1.19 million
Net Margins
8.38%
Pretax Margin
8.45%
Return on Equity
10.60%
Return on Assets
8.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.07
Quick Ratio
2.71

Sales & Book Value

Annual Sales
$18.79 million
Price / Sales
2.35
Cash Flow
$0.12 per share
Price / Cash Flow
33.60
Book Value
$1.10 per share
Price / Book
3.69

Miscellaneous

Outstanding Shares
10,860,000
Free Float
10,132,000
Market Cap
$44.09 million
Optionable
Not Optionable
Beta
1.55

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners